	US 11,911,464 B2
	Anti-parasitic immunological compositions
Paul Davis, Omaha, NE (US); and Samer Al-Murrani, Overland Park, KS (US)
Assigned to Prommune, Inc., Topeka, KS (US); and Board of Regents of the University of Nebraska, Lincoln, NE (US)
Appl. No. 17/275,892
Filed by Prommune, Inc., Topeka, KS (US); and Board of Regents of the University of Nebraska, Lincoln, NE (US)
PCT Filed Sep. 13, 2019, PCT No. PCT/US2019/050963 § 371(c)(1), (2) Date Mar. 12, 2021, PCT Pub. No. WO2020/056229, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/731,353, filed on Sep. 14, 2018.
Prior Publication US 2021/0290761 A1, Sep. 23, 2021
Int. Cl. A61K 39/39 (2006.01); A61P 33/02 (2006.01); A61K 39/002 (2006.01); A61K 39/005 (2006.01); A61K 39/008 (2006.01); A61K 39/012 (2006.01); A61K 39/015 (2006.01); A61K 39/018 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39 (2013.01) [A61K 39/002 (2013.01); A61K 39/005 (2013.01); A61K 39/008 (2013.01); A61K 39/012 (2013.01); A61K 39/015 (2013.01); A61K 39/018 (2013.01); A61P 33/02 (2018.01); A61K 2039/55516 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/627 (2013.01)]

11 Claims

1. A composition for inducing an immune response to Toxoplasma gondii infection, the composition comprising a plurality of peptides dispersed in a pharmaceutically acceptable carrier, said peptides each comprising an N-terminal peptide antigen conjugated to a C-terminal peptide adjuvant via a protease-cleavable linker,

wherein said N-terminal peptide antigen is selected from the group consisting of SFKDILPKLSENPWQ (SEQ ID NO:19), EEVIDTMKSMQRDEE (SEQ ID NO:20), CAELCDPSNKPGHLL (SEQ ID NO:21), KRVTCGYPESGPVNL (SEQ ID NO:22), DRRPLHPGSVNEFDF (SEQ ID NO:23), and GLVAAALPQFATAAT (SEQ ID NO:24), and

wherein said C-terminal peptide adjuvant is EP67 YSFKDMP(MeL)aR (SEQ ID NO:2),

said plurality of peptides comprising at least two or more different peptides each having a different N-terminal peptide antigen.